공고 • Jun 04

Cardlytics, Inc. Receives Notice of Delisting and Reverse Stock Split to Regain Compliance

On June 3, 2026, Cardlytics, Inc., a Delaware corporation (the Company), received a letter from the Listing Qualifications Staff (the Nasdaq Staff) of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that for the last 30 consecutive business days, the bid price of the Company's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until November 30, 2026 (the Compliance Date), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of ten consecutive business days before the Compliance Date. If the Company's common stock does not achieve compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split. However, if it appears to the Nasdaq Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for the additional compliance period, and the Company does not regain compliance by the Compliance Date, the Nasdaq Global Market will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the panel, such appeal would be successful. The Company intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price rule, including by effecting a reverse stock split. On June 3, 2026, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the Charter Amendment) with the Secretary of State of the State of Delaware to effect (i) a reverse stock split at a ratio of 1-for-10 (the Reverse Stock Split) and (ii) a corresponding reduction in the total number of authorized shares of common stock from 100,000,000 shares to 10,000,000 shares (the Authorized Shares Reduction). The Reverse Stock Split and the Authorized Shares Reduction were authorized by the stockholders of the Company at the Company's Annual Meeting of Stockholders held on May 20, 2026. Pursuant to the Charter Amendment, effective at 5:00 p.m. Eastern Time on June 5, 2026 (the Effective Time), every 10 shares of the Company's issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in par value per share. The Company's common stock will begin trading on The Nasdaq Global Market on a split-adjusted basis when the market opens on June 8, 2026. The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 14161W303. As of June 1, 2026, there were 58,078,634 shares of common stock outstanding. Immediately following the Reverse Stock Split, there will be approximately 5,807,863 shares of common stock outstanding (subject to adjustment due to the effect of cashing out fractional shares as described above).

공고 • Sep 11

Cardlytics, Inc. Settles Lawsuit With Amit Jain

Cardlytics, Inc. had previously disclosed in connection with the acquisition of Bridg, Inc. by Cardlytics, Inc. in 2021, the Company assumed certain indemnification obligations to former officers and directors of Bridg pursuant to existing indemnification agreements. On July 9, 2026, Amit Jain, the founder and former Chief Executive Officer and director of Bridg, filed a verified complaint against the Company in the Court of Chancery of the State of Delaware (Case No. 2026-0896-TJF) seeking advancement and indemnification for fees and expenses incurred in connection with the action captioned DailyGobble, Inc. v. Amit Jain, et al., No. 22STCV15317, in the Superior Court of the State of California, which was resolved through a settlement under which Mr. Jain's allocated portion was approximately $5.3 million, and related insurance coverage actions involving Scottsdale Insurance Company. On September 4, 2026, the Company and Mr. Jain entered into a settlement and release agreement, pursuant to which the parties agreed to settle Mr. Jain's claim for an aggregate amount of $6.4 million, consisting of Mr. Jain's allocated portion of the DailyGobble Action settlement and associated costs, plus $1.1 million in satisfaction of legal fees incurred related to the DailyGobble Action. This aggregate settlement amount is consistent with the $6.5 million accrual (comprised of a $5.3 million accrual for the settlement and a $1.2 million accrual for attorney's fees) recorded by the Company as of June 30, 2026, the Company is seeking insurance reimbursement that it believes should apply to this matter. The Settlement Agreement, dated September 4, 2026, is entered into by and among Cardlytics, Inc. and Amit Jain. Cardlytics and Mr. Jain shall each be referred to herein as a Settling Party, and collectively as the Settling Parties. On or before September 4, 2026, Cardlytics shall initiate payment via wire transfer of the aggregate sum of $6,441,649.40, paid in total to Mr. Jain pursuant to payment instructions attached hereto as Exhibit B, consisting of (a) $5,250,000 representing Mr. Jain's portion of the DailyGobble Settlement and associated borrowing costs of $51,663.60, plus (b) $1,139,985.80 in satisfaction of Cardlytics's obligation to pay Michelman's fees incurred in representing Mr. Jain up to the date of this Agreement. Cardlytics agrees to advance Mr. Jain's reasonable attorneys' fees and costs incurred in connection with the Scottsdale Actions and Delaware Action that have accrued through the date of this Agreement, pursuant to and in accordance with the terms of the Indemnification Agreement. Further, Cardlytics agrees to advance Mr. Jain's reasonable attorneys' fees and costs in connection with the Scottsdale Actions, Delaware Action, and the settlement of the DailyGobble Action on a going-forward basis, if any, pursuant to and in accordance with the terms of the Indemnification Agreement and the Fitracks order in the Delaware Action. Mr. Jain agrees to execute such further documents and take such further actions as Cardlytics may reasonably request to effectuate this assignment, including making any filings in the Scottsdale Action to substitute parties or counsel. Mr. Jain agrees that, promptly following the effective assignment of the Scottsdale Actions to Cardlytics pursuant to Section 2.1, he shall dismiss the Implied Covenant Claims. Within two business days of receipt by Mr. Jain of the settlement payment described in Section 1.1, the Settling Parties shall execute and Mr. Jain shall file in the Delaware Action the Stipulation and Proposed Order of Dismissal with Prejudice attached hereto as Exhibit C. The Dismissal with Prejudice filed in the Delaware Action will not preclude Mr. Jain from enforcing his rights to advancement or indemnification under the Indemnification Agreement or Delaware law for anything related to his cooperation in the Scottsdale Actions or the Fitracks order for fees and costs accrued pursuant to Section 1.2. Effective upon Cardlytics's payment of the amount set forth in Section 1.1, Mr. Jain, on behalf of himself and his heirs, executors, administrators, successors, and assigns, hereby irrevocably and unconditionally releases, acquits, and forever discharges Cardlytics, and its current and former officers, directors, employees, agents, affiliates, subsidiaries, parents, successors, and assigns from any and all claims, demands, actions, causes of action, damages, liabilities, judgments, liens, costs, expenses, and attorneys' fees of any kind or nature whatsoever, whether known or unknown, suspected or unsuspected, asserted or unasserted, contingent or non-contingent, that Mr. Jain ever had, now has, or may hereafter have against the Cardlytics Released Parties, arising out of or related to the DailyGobble Action, the Scottsdale Actions, or the Delaware Action, including but not limited to any claims for advancement, indemnification, or fees-on-fees under the Indemnification Agreement related to the DailyGobble Action, the Scottsdale Actions, or the Delaware Action provided, however, that this release shall not apply to (a) fees and costs in Section 1.2, (b) any claims for advancement or indemnification in the Scottsdale Actions and Delaware Action on a going-forward basis, if any, pursuant to and in accordance with the terms of the Indemnification Agreement and the Fitracks order in the Delaware Action (c) any claims to enforce the terms of this Agreement, or (d) any rights to advancement or indemnification under the Indemnification Agreement or Delaware law with respect to any future proceedings that are unknown and do not exist as of the date of this Agreement. Effective upon Mr. Jain's dismissal of the Delaware Action pursuant to Section 3.1, Cardlytics, on behalf of itself and its affiliates, subsidiaries, parents, successors, and assigns, hereby irrevocably and unconditionally releases, acquits, and forever discharges Mr. Jain, and his heirs, executors, administrators, successors, and assigns from any and all claims, demands, actions, causes of action, damages, liabilities, judgments, liens, costs, expenses, and attorneys' fees of any kind or nature whatsoever, whether known or unknown, suspected or unsuspected, asserted or unasserted, contingent or non-contingent, that Cardlytics ever had, now has, or may hereafter have against the Mr. Jain Released Parties, arising out of or related to the Delaware Action, the DailyGobble Action, or the Scottsdale Actions provided, however, that this release shall not apply to (a) any claims made by Mr. Jain for advancement or indemnification in the Delaware Action on a going-forward basis, if any, pursuant to and in accordance with the terms of the Indemnification Agreement and the Fitracks order in the Delaware Action, or (b) any claims to enforce the terms of this Agreement.

이자보상배율	n/a
현금	US$28.04m
자본	-US$16.00m
총부채	US$250.79m
총자산	US$234.79m

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/09/21 00:07
종가	2026/09/21 00:00
수익	2026/06/30
연간 수익	2025/12/31

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

분석가	기관
Omar Dessouky	BofA Global Research
Jason Kreyer	Craig-Hallum Capital Group LLC
Robert Coolbrith	Evercore ISI

Cardlytics 대차대조표 건전성

재무 건전성 기준 점검 2/6

핵심 정보

최근 재무 건전성 업데이트

Cardlytics, Inc. Receives Notice of Delisting and Reverse Stock Split to Regain Compliance

Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?

Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Recent updates

CDLX: Indemnification Settlement And Earnings Outlook Will Support Future Repricing Potential

Cardlytics, Inc. Settles Lawsuit With Amit Jain

CDLX: Lower Fair Value And Revenue Guidance Will Shape Balanced Return Outlook

CDLX: Reverse Split And Margin Outlook Will Shape Future Repricing

Consensus EPS estimates upgraded to US$3.88 loss, revenue downgraded

Price target decreased by 30% to US$7.50

Cardlytics, Inc. Provides Unaudited Earnings Guidance for the Third Quarter of 2026

CDLX: Reverse Split And Profitability Outlook Will Drive Future Repricing

Second quarter 2026 earnings: EPS misses analyst expectations

Cardlytics Inc. Announces Appointment of Chris Cheng to Chief Legal Officer, Effective August 3, 2026

Cardlytics, Inc. to Report Q2, 2026 Results on Aug 05, 2026

CDLX: Reverse Split And Margin Outlook Will Support A Higher Price

CDLX: Reverse Split And Nasdaq Compliance Efforts Will Drive Future Repricing Potential

CDLX: Reverse Split And Margin Outlook Will Drive Future Repricing

Cardlytics, Inc. Receives Notice of Delisting and Reverse Stock Split to Regain Compliance

CDLX: Reset Expectations And Partner Exit Will Drive Future Repricing

Consensus EPS estimates upgraded to US$0.81 loss, revenue downgraded

High number of new and inexperienced directors

CDLX: Reset Guidance And Banking Shifts Will Drive Future Repricing Potential

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2026

CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing

Cardlytics, Inc. to Report Q1, 2026 Results on May 07, 2026

CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential

CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing

Cardlytics, Inc., Annual General Meeting, May 20, 2026

CDLX: Reset Guidance And One Bank Exit Will Define Upside Potential

CDLX: Reset Expectations And CFO Return Will Support Future Rerating

Cardlytics, Inc. to Report Q4, 2025 Results on Mar 04, 2026

Cardlytics, Inc. (NASDAQ:CDLX) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Cardlytics Inc. Announces Appointment of David Evans as Chief Financial Officer, Effective January 12, 2026

Cardlytics, Inc. Announces Resignation of Chief Financial Officer Alexis DeSieno, Effective by March 6, 2026

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2025

Cardlytics, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Cardlytics: Debt Overhang Casts Shadow On Upside

Cardlytics Announces Workforce Reductions as Part of Organizational Realignment and Cost Savings Initiative

Bank Partnerships And Data-Driven Marketing Will Shape Future Markets

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter of 2025

Cardlytics, Inc. to Report Q2, 2025 Results on Aug 06, 2025

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX) As Its Stock Soars 64%

Cardlytics Introduces New Customer Insights Dashboards Within the Cardlytics Insights Portal

Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?

Cardlytics, Inc.(NasdaqGM:CDLX) dropped from Russell 2500 Growth Index

Cardlytics, Inc. (NASDAQ:CDLX) Soars 30% But It's A Story Of Risk Vs Reward

Cardlytics Launches Cardlytics Rewards Platform and Expands Publisher Base Beyond Financial Institutions

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2025

Cardlytics, Inc. to Report Q1, 2025 Results on May 07, 2025

Why Investors Shouldn't Be Surprised By Cardlytics, Inc.'s (NASDAQ:CDLX) 30% Share Price Plunge

Cardlytics, Inc., Annual General Meeting, May 20, 2025

US Neobank And Taiwan Office Will Unlock New Markets

Cardlytics, Inc. Provides Earnings Guidance for the First Quarter of 2025

Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?

Cardlytics, Inc. to Report Q4, 2024 Results on Mar 12, 2025

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX)

Cardlytics: Short-Term Headwinds Drive Long-Term Success

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Cardlytics, Inc. Investors

At US$3.35, Is It Time To Put Cardlytics, Inc. (NASDAQ:CDLX) On Your Watch List?

Cardlytics Continues Revenue Contraction Amid Worsening Economics

Estimating The Intrinsic Value Of Cardlytics, Inc. (NASDAQ:CDLX)

Cardlytics, Inc. Reports Unaudited Consolidated Impairment of Goodwill and Intangible Assets for the Three Months Ended September 30, 2024

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Cardlytics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2024

Cardlytics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00